Related Experiment Video
Updated: Feb 15, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Identification of CDK2 as a novel target in treatment of prostate cancer
Xifeng Yin1, Jun Yu2, Yang Zhou1
1Department of Urology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Aim:
This study aims the potential gene involved in the metastasis of prostate cancer (Pca).
Methods:
PubMed GEO datasets (GSE6605 and GSE6606) were downloaded. We used multiple bioinformatics methods to screen differentially expressed genes in Pca. Gene network was built by STRING and visualized by Cytoscape. All of the hub genes were analyzed by cBioPortal. Inhibition of CDK2 including siRNA, inhibitor and cas9-induced CDK2 knockout was followed by an invasion assay. Downstream genes of CDK2 were analyzed by western blot.
Results:
Sequencing data were analyzed to screen the genes with expression alterations. The top genes were validated in our samples. 11 hub genes were screened out. Among these genes, STAT3 and CDK2 were significantly associated with recurrence. Further study suggested that inhibition of CDK2 reduced invasion of Pca cell lines. The invasion ability was rescued after reintroduction of CDK2.
Conclusion:
These data indicated that CDK2 was a crucial factor in metastasis of Pca and might be a novel therapy target. [Formula: see text].
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Methods of Classification and Identification
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Cancer

